A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it ...

The FDA’s clearance marks a significant regulatory milestone for Jupiter, enabling the Company to begin enrollment in its exploratory Phase 2a trial designed to evaluate the safety and tolerability of ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has ...

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate ...

Following publication of BioProtect's pivotal randomized trial in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) and presentation of the long-term quality-of-life ...

The current model of managing corporate identities is unprepared for a wave of AI agents gaining access to privileged resources.

Columbus Business First President & Publisher Nick Fortine speaks with experts from Trace3 and Cisco about how organizations ...

Supercharging recruitment processes has long been RPO’s calling card but with AI promising to transform recruitment, where ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

Jaya Biosciences receives US patent for novel methods of treating neurological diseases: South San Francisco, California Friday, November 7, 2025, 13:00 Hrs [IST] Jaya Biosciences ...

USA: Results from the pivotal STORM-PE randomized controlled trial, presented as a Late-Breaking Clinical Trial at TCT 2025, ...